Skip to main content
Premium Trial:

Request an Annual Quote

Gene Network Sciences to Help Murex Develop Cancer Drugs

NEW YORK, June 2 (GenomeWeb News) - Gene Network Sciences will help Murex Pharmaceuticals co-develop cancer therapeutics, Murex said yesterday.

 

GNS uses computer models to study cancer therapies and Murex will use its technology to create computer-based models to help it identify and validate cancer targets. Murex will then design shRNA-based vaccines that halt cancer growth.

 

GNS scientists will work directly with Murex teams at Murex's research and development facilities in Texas.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.